These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 24432510)

  • 41. Cyclosporine A and cyclosporine G enhance IgG rheumatoid factor production in MRL/lpr mice.
    Gunn HC; Hiestand PC
    Transplant Proc; 1988 Jun; 20(3 Suppl 4):238-42. PubMed ID: 3260051
    [No Abstract]   [Full Text] [Related]  

  • 42. Alemtuzumab in T-cell lymphoproliferative disorders.
    Dearden CE; Matutes E
    Best Pract Res Clin Haematol; 2006; 19(4):795-810. PubMed ID: 16997184
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Proposal for a new clinical entity, IgG4-positive multiorgan lymphoproliferative syndrome: analysis of 64 cases of IgG4-related disorders.
    Masaki Y; Dong L; Kurose N; Kitagawa K; Morikawa Y; Yamamoto M; Takahashi H; Shinomura Y; Imai K; Saeki T; Azumi A; Nakada S; Sugiyama E; Matsui S; Origuchi T; Nishiyama S; Nishimori I; Nojima T; Yamada K; Kawano M; Zen Y; Kaneko M; Miyazaki K; Tsubota K; Eguchi K; Tomoda K; Sawaki T; Kawanami T; Tanaka M; Fukushima T; Sugai S; Umehara H
    Ann Rheum Dis; 2009 Aug; 68(8):1310-5. PubMed ID: 18701557
    [TBL] [Abstract][Full Text] [Related]  

  • 44. 2-Chlorodeoxyadenosine: a potent antimetabolite with major activity in the treatment of indolent lymphoproliferative disorders.
    Saven A; Piro LD
    Hematol Cell Ther; 1996 Dec; 38 Suppl 2():S93-101. PubMed ID: 9137962
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Post transplant lymphoproliferative disease: detection of tumor by Tc99m sestaMIBI and treatment with rituximab.
    Paydas S; Yapar Z; Ergin M; Guney IB; Disel U; Yavuz S
    Bone Marrow Transplant; 2005 Feb; 35(3):317-8. PubMed ID: 15592492
    [No Abstract]   [Full Text] [Related]  

  • 46. Lymphoproliferative disorders associated with hypereosinophilia.
    Roufosse F; Garaud S; de Leval L
    Semin Hematol; 2012 Apr; 49(2):138-48. PubMed ID: 22449624
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Post-transplant lymphoproliferative disease in children following solid organ transplant and rituximab--the final answer?
    Gross TG
    Pediatr Transplant; 2007 Sep; 11(6):575-7. PubMed ID: 17663676
    [No Abstract]   [Full Text] [Related]  

  • 48. Severe and prolonged myeloid haematopoietic toxicity with myelodysplastic features following alemtuzumab therapy in patients with peripheral T-cell lymphoproliferative disorders.
    Gibbs SD; Westerman DA; McCormack C; Seymour JF; Miles Prince H
    Br J Haematol; 2005 Jul; 130(1):87-91. PubMed ID: 15982349
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Successful treatment of autoimmune and lymphoproliferative complications of patients with intrinsic B-cell immunodeficiencies with Rituximab.
    Hennig C; Baumann U; Ilginus C; Horneff G; Foell J; Hansen G
    Br J Haematol; 2010 Feb; 148(3):445-8. PubMed ID: 19922533
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Novel treatment with rituximab of oropharyngeal posttransplant lymphoproliferative disorder after heart transplantation.
    Kaczmarek I; Beiras-Fernandez A; Sadoni S; Bengel D; Deutsch MA; Meiser B; Reichart B
    Exp Clin Transplant; 2005 Dec; 3(2):381-4. PubMed ID: 16417448
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Successful treatment of post-transplant lymphoproliferative disorder in autologous blood stem cell transplant recipients.
    Jenkins D; DiFrancesco L; Chaudhry A; Morris D; Glück S; Jones A; Woodman R; Brown CB; Russell J; Stewart DA
    Bone Marrow Transplant; 2002 Sep; 30(5):321-6. PubMed ID: 12209355
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Rituximab with peripheral blood stem cell transplantation in CD20 lymphoproliferative disorders.
    Mazza P; Palazzo G; Amurri B; Pricolo G; Prudenzano A; Stani L
    Haematologica; 2001 Oct; 86(10):1104-5. PubMed ID: 11602420
    [No Abstract]   [Full Text] [Related]  

  • 53. Efficiency of antiviral therapy plus IVIG in a case of primary EBV infection associated PTLD refractory to rituximab, chemotherapy, and antiviral therapy alone.
    Trappe R; Riess H; Anagnostopoulos I; Neuhaus R; Gärtner BC; Pohl H; Müller HP; Jonas S; Papp-Vary M; Oertel S
    Ann Hematol; 2009 Feb; 88(2):167-72. PubMed ID: 18636261
    [No Abstract]   [Full Text] [Related]  

  • 54. [Immunological analysis and experimental immunotherapy for HTLV-I-infected T lymphoproliferative disease in a rat model].
    Ohashi T; Hanabuchi S; Kannagi M
    Nihon Rinsho Meneki Gakkai Kaishi; 2002 Feb; 25(1):65-9. PubMed ID: 11963182
    [No Abstract]   [Full Text] [Related]  

  • 55. Introduction to lymphoproliferative disorders in adults.
    Leclair SJ; Ferreira K
    Clin Lab Sci; 2013; 26(4):181. PubMed ID: 24432510
    [No Abstract]   [Full Text] [Related]  

  • 56. [Kinetic and immunological considerations on the therapy of immunoproliferative disorders].
    Pileri A; Boccadoro M; Conte P
    Recenti Prog Med; 1979 Feb; 66(2):103-15. PubMed ID: 375339
    [No Abstract]   [Full Text] [Related]  

  • 57. [The significance of cellular surface markers in lymphoproliferative disorders].
    Aderka D; Pinkhas J
    Harefuah; 1982 Apr; 102(7):307-10. PubMed ID: 6981541
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.